Clinical Trial Search

Primary: Proportion of All Participants Negative for Viral RNA on Day 5 — 115; 105 participants — p=0.42

Primary: Number of Participants With Genotypic Resistance — 44; 1; 0; 2 participants

Primary: Number of Seasonal Influenza A and /or B Cases by Age Group, in Panama (Using the Data Reported Via National Influenza Surveillance Program) — 448; 120; 123; 47…

Primary: Number of Laboratory-confirmed Influenza Infections — .22; .14 infections

Primary: Serum Haemagglutination-inhibition (HI) Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2) — 24.4; 15.6; 14.6; 9.8 Titer

Primary: Frequency Counts and Percentage of Subjects With Adverse Events — 6; 6; 1; 3 Participants

Primary: Age Adjusted Percentage of Participants With a Physician Visit Due to Any Diagnosis Within 30 Days of the Index Date of the Confirmed Influenza A and B Cases in the…

Primary: Viral Copy Number in 30-minute Exhaled Breath Sample — 38,000; 12,000 Fine aerosol RNA copy number

Primary: Percentage of Participants With Virus Detectable by Quantitative PCR (qPCR) in Nasopharyngeal (NP) Swabs at Day 3 -- Team Collected Samples — 99; 131 Participants…

Primary: Measure Antibody Concentrations in Immunosuppressed IBD Patients Who Receive High Dose and Standard of Care Dose Influenza Vaccine — 160; 160; 160; 160 Antibody Titer

Primary: Hospitalization — 26; 2 Participants

Primary: Seroprotection Based on Hemagglutination Antibody Inhibition (HAI) — 32; 22 Participants

Primary: Number of Patients in Each of 6 Clinical Status Categories on Day 7 — 3; 2; 6; 11 Participants — p=.33

Primary: Number of Subjects With Laboratory-confirmed Influenza Presenting With an Acute Respiratory Illness (ARI) and/or Isolated Fever — 120; 11 Participants

Primary: Change in Inflammatory Markers From Time Zero to 72 Hours — 2.4; 3.46; 0.91; 0.57 pg/ml — p=0.611

Primary: MAARI Rate During the Epidemic Period (2007-2008) — 12503; 18998 Number of MAARI

Primary: Frequency of CD4 T Cells With a Given Functional Potential — 0.70; 0.55; 0.52; 0.38 Percentage

Primary: Number of PCR-confirmed Influenza Infections — 17; 3 Participants

Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Each HA-F A/Sing Product Administration — 4; 3; 7; 9 Participants

Primary: Percent MMID — 0; 0; 20; 47 percentage of participants

Primary: Area Under the Curve (AUC) of Viral Shedding — 48.56; 25.53 ViralLoad(log(copies/ml))per time(hours) — p=0.31

Primary: Number and Percentage of Participants With Symptomatic Influenza Virus Infection After Challenge. — 4; 5; 28; 0 Participants

Primary: Percentage of Participants Excreting Resistant Virus — 26.3; 35.3 percentage of participants — p=0.825

Primary: Number of Participants With Mild to Moderate Influenza Disease (MMID) — 23; 13; 15; 19 Participants — p=0.03

Primary: Cost for the Medical Management of Patients — 581; 661 USD

Primary: Number of Participants With a Four-fold Increase in Stem-specific Antibody Titers (H5, Hemagglutinin Antibody) Against H5N1 at Day 29 After Vaccination With the Seasonal…

Primary: Number of Patients With Clinical Phenotype Presenting Also a Sequential Activation of Immune/Infammatory Pathways. — 131 Participants

Primary: Number of Participants Having Adverse Events — 0; 1; 1; 1 Participants

Primary: Percentage of Participants With Virus Detectable by Quantitative PCR (qPCR) in Nasopharyngeal (NP) Swabs — 40; 50 percentage of participants analyzed — p=0.046

Primary: Percentage of Participants With Symptomatic, Laboratory-confirmed Influenza Virus Infection (Vaccine-matched Strains). — 6.7; 15.8 percentage of participants — p=<0.0001